Latest Weight-Loss Drug , Faces Shortages .
The United States Food and Drug Administration
(FDA) says that high demand has left the latest
weight-loss drug, Zepbound, in short supply.
'Newsweek' reports that the Eli Lilly product
is expected to experience limited availability
through Q2 of 2024 as surging demand has
outpaced the manufacturer's expectations.
We have experienced
an unparalleled surge in
demand for our type 2
diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.
We recognize this situation may
cause a disruption in peoples'
treatment regimens and are
working with purpose and
urgency to help meet
the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.
The FDA said that Novo Nordisk's weight-loss
drug, Wegovy, is also experiencing a
widespread supply shortage with no end
in sight for the drug's limited availability.
By the year 2030, 'Newsweek' reports
that the weight-loss drug market is
expected to grow to about $100 billion.
We expect our investments
in manufacturing and supply
capacity to progressively increase
production of our medicines
throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.
Over the past year, manufacturer Eli Lilly
has already seen share prices rise over 102%.
The company has announced plans
to expand operations to meet increased
demand for its incretin products which are
used in the firm's diabetes treatments. .
Incretin mimics gut hormones
that regulate blood sugar
while also suppressing appetite
